Study Finds Children Have Better Outcomes with Kidney Transplants from Living Donors

August 30, 2022 10:45:07

A new study has found that pediatric patients who undergo kidney transplants may have better outcomes if the donated kidney comes from a biologically unrelated and living donor in comparison to a deceased donor. For their research, the scientists reviewed data obtained from the Organ Procurement and Transplantation Network database during the period between January 2001 and September 2021. The investigators examined more than 12,000 children who had received kidney transplants during the study period.

Of the total number of children, 61% received kidneys from deceased donors, 36% received kidneys from living related donors and less than 3% received kidneys from a living unrelated donor. The majority of the living related donors were parents and other relatives.

The scientists compared the long-term outcomes of children whose kidneys were transplanted from living related donors, deceased donors and living unrelated donors. They also compared graft failure rates in these pediatric patients as well as mortality rates. Graft failure occurs when a transplanted organ is rejected by its recipient’s body. The study did not include children whose grafts had failed on the day of the surgical procedure.

The researchers used the age of the recipients as a graft-loss predictor, finding that during the first post-transplant year, infants and preteens had a higher risk of graft failure, in comparison to teens. They also found that graft survival was highest in living unrelated and related donors and lowest in deceased donor transplants, noting that even when HLA matching between the recipient and their donor was poor, recipients with living donor transplants fared better compared to those with transplants from deceased donors. HLA matching is used to match donors and patients for cord blood or bone marrow transplants.

In addition to this, the investigators discovered that the number of living unrelated donors increased significantly between 1987 and 2017, moving from 1.3% to 31.4%.

The senior author of the study, Lavjay Butani, stated that their findings would help ease any concerns and fears that centers had about accepting organs from living unrelated donors. Butani, the pediatric nephrology chief at UC Davis’ Children’s Hospital, explained that organs from living donors were superior to those from deceased donors.

In the report, Professor Daniel Tancredi, coauthor of the study, added that the findings were important for children who were vulnerable and would benefit greatly from receiving the best possible available donor organs. The research’s findings were reported in the “Pediatric Transplantation” journal.

Several companies, including Aditxt Inc. (NASDAQ: ADTX), are studying various approaches, such as modulating immune system function, with the goal of decreasing the rates of transplant organ rejections and helping patients enjoy a better quality of life with the new organs they have received.

NOTE TO INVESTORS: The latest news and updates relating to Aditxt Inc. (NASDAQ: ADTX) are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.